

Triple-Negative Breast Cancer Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/T1EC22B9E368EN.html>

Date: March 2022

Pages: 62

Price: US\$ 3,250.00 (Single User License)

ID: T1EC22B9E368EN

Abstracts

This report contains market size and forecasts of Triple-Negative Breast Cancer Treatment in Global, including the following market information:

Global Triple-Negative Breast Cancer Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Triple-Negative Breast Cancer Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Alkylating Agents Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Triple-Negative Breast Cancer Treatment include Celgene, Roche, Immunomedics GmbH, Merck & Co., Inc., F. Hoffmann-La Roche Ltd and Eisai Co., Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Triple-Negative Breast Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends,

drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Triple-Negative Breast Cancer Treatment Market, by Type, 2017-2022,
2023-2028 (\$ millions)

Global Triple-Negative Breast Cancer Treatment Market Segment Percentages, by
Type, 2021 (%)

Alkylating Agents

Plant Products

Microorganism Products

Antimetabolites

Microtubule Stablizing Agents

Global Triple-Negative Breast Cancer Treatment Market, by Application, 2017-2022,
2023-2028 (\$ millions)

Global Triple-Negative Breast Cancer Treatment Market Segment Percentages, by
Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Global Triple-Negative Breast Cancer Treatment Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Triple-Negative Breast Cancer Treatment Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Triple-Negative Breast Cancer Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Triple-Negative Breast Cancer Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Celgene

Roche

Immunomedics GmbH

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd

Eisai Co., Ltd

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Triple-Negative Breast Cancer Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Triple-Negative Breast Cancer Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT OVERALL MARKET SIZE

- 2.1 Global Triple-Negative Breast Cancer Treatment Market Size: 2021 VS 2028
- 2.2 Global Triple-Negative Breast Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Triple-Negative Breast Cancer Treatment Players in Global Market
- 3.2 Top Global Triple-Negative Breast Cancer Treatment Companies Ranked by Revenue
- 3.3 Global Triple-Negative Breast Cancer Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Triple-Negative Breast Cancer Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Triple-Negative Breast Cancer Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Triple-Negative Breast Cancer Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Triple-Negative Breast Cancer Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Triple-Negative Breast Cancer Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Triple-Negative Breast Cancer Treatment Market Size Markets, 2021 & 2028

4.1.2 Alkylating Agents

4.1.3 Plant Products

4.1.4 Microorganism Products

4.1.5 Antimetabolites

4.1.6 Microtubule Stabilizing Agents

4.2 By Type - Global Triple-Negative Breast Cancer Treatment Revenue & Forecasts

4.2.1 By Type - Global Triple-Negative Breast Cancer Treatment Revenue, 2017-2022

4.2.2 By Type - Global Triple-Negative Breast Cancer Treatment Revenue, 2023-2028

4.2.3 By Type - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Triple-Negative Breast Cancer Treatment Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.2 By Application - Global Triple-Negative Breast Cancer Treatment Revenue & Forecasts

5.2.1 By Application - Global Triple-Negative Breast Cancer Treatment Revenue, 2017-2022

5.2.2 By Application - Global Triple-Negative Breast Cancer Treatment Revenue, 2023-2028

5.2.3 By Application - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Triple-Negative Breast Cancer Treatment Market Size, 2021 & 2028

6.2 By Region - Global Triple-Negative Breast Cancer Treatment Revenue & Forecasts

6.2.1 By Region - Global Triple-Negative Breast Cancer Treatment Revenue, 2017-2022

6.2.2 By Region - Global Triple-Negative Breast Cancer Treatment Revenue, 2023-2028

6.2.3 By Region - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Triple-Negative Breast Cancer Treatment Revenue, 2017-2028

6.3.2 US Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.3.3 Canada Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.3.4 Mexico Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Triple-Negative Breast Cancer Treatment Revenue, 2017-2028

6.4.2 Germany Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.3 France Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.4 U.K. Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.5 Italy Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.6 Russia Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.4.8 Benelux Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Triple-Negative Breast Cancer Treatment Revenue, 2017-2028

6.5.2 China Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.5.3 Japan Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.5.4 South Korea Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.5.6 India Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Triple-Negative Breast Cancer Treatment Revenue, 2017-2028

6.6.2 Brazil Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.6.3 Argentina Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Triple-Negative Breast Cancer Treatment

Revenue, 2017-2028

6.7.2 Turkey Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.7.3 Israel Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

6.7.5 UAE Triple-Negative Breast Cancer Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Celgene

7.1.1 Celgene Corporate Summary

7.1.2 Celgene Business Overview

7.1.3 Celgene Triple-Negative Breast Cancer Treatment Major Product Offerings

7.1.4 Celgene Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.1.5 Celgene Key News

7.2 Roche

7.2.1 Roche Corporate Summary

7.2.2 Roche Business Overview

7.2.3 Roche Triple-Negative Breast Cancer Treatment Major Product Offerings

7.2.4 Roche Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.2.5 Roche Key News

7.3 Immunomedics GmbH

7.3.1 Immunomedics GmbH Corporate Summary

7.3.2 Immunomedics GmbH Business Overview

7.3.3 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Major Product Offerings

7.3.4 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.3.5 Immunomedics GmbH Key News

7.4 Merck & Co., Inc.

7.4.1 Merck & Co., Inc. Corporate Summary

7.4.2 Merck & Co., Inc. Business Overview

7.4.3 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Major Product Offerings

7.4.4 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.4.5 Merck & Co., Inc. Key News

7.5 F. Hoffmann-La Roche Ltd

7.5.1 F. Hoffmann-La Roche Ltd Corporate Summary

7.5.2 F. Hoffmann-La Roche Ltd Business Overview

7.5.3 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Major Product Offerings

7.5.4 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.5.5 F. Hoffmann-La Roche Ltd Key News

7.6 Eisai Co., Ltd

7.6.1 Eisai Co., Ltd Corporate Summary

7.6.2 Eisai Co., Ltd Business Overview

7.6.3 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Major Product Offerings

7.6.4 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.6.5 Eisai Co., Ltd Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Triple-Negative Breast Cancer Treatment Market Opportunities & Trends in Global Market

Table 2. Triple-Negative Breast Cancer Treatment Market Drivers in Global Market

Table 3. Triple-Negative Breast Cancer Treatment Market Restraints in Global Market

Table 4. Key Players of Triple-Negative Breast Cancer Treatment in Global Market

Table 5. Top Triple-Negative Breast Cancer Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Triple-Negative Breast Cancer Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Triple-Negative Breast Cancer Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Triple-Negative Breast Cancer Treatment Product Type

Table 9. List of Global Tier 1 Triple-Negative Breast Cancer Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Triple-Negative Breast Cancer Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Triple-Negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Triple-Negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Triple-Negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Triple-Negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Triple-Negative Breast Cancer Treatment

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Triple-Negative Breast Cancer Treatment

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Celgene Corporate Summary

Table 31. Celgene Triple-Negative Breast Cancer Treatment Product Offerings

Table 32. Celgene Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Roche Corporate Summary

Table 34. Roche Triple-Negative Breast Cancer Treatment Product Offerings

Table 35. Roche Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Immunomedics GmbH Corporate Summary

Table 37. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Product Offerings

Table 38. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Merck & Co., Inc. Corporate Summary

Table 40. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Product Offerings

Table 41. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. F. Hoffmann-La Roche Ltd Corporate Summary

Table 43. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Product Offerings

Table 44. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Eisai Co., Ltd Corporate Summary

Table 46. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Product Offerings

Table 47. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Triple-Negative Breast Cancer Treatment Segment by Type in 2021
- Figure 2. Triple-Negative Breast Cancer Treatment Segment by Application in 2021
- Figure 3. Global Triple-Negative Breast Cancer Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Triple-Negative Breast Cancer Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Triple-Negative Breast Cancer Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Triple-Negative Breast Cancer Treatment Revenue in 2021
- Figure 8. By Type - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028
- Figure 12. US Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 24. China Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Triple-Negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Celgene Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Roche Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Triple-Negative Breast Cancer Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/T1EC22B9E368EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T1EC22B9E368EN.html>